Enfold's 5-MeO-DMT Research Study

Enfold is partnered with UHN to explore the impact of 5-MeO-DMT in a multi-day setting.

Enfold is grateful to be partnered with The University Health Network Psychedelic Psychotherapy Research Group (UHN PPRG), an esteemed non-profit academic research program affiliated with the University of Toronto.

Together, we’re exploring the impact of 5-MeO-DMT combined with somatic and psychospiritual therapeutic modalities in a relational multi-day format.

Enfold initiated this research project with Emma Hapke and her team at UHN PPRG because we felt a need to bring a wider perspective to the psychedelic research space.

We saw that most research in the space was isolating the psychedelic substance from the set and setting it was delivered in, which felt incomplete. There is an overemphasis on the substances themselves, and not enough connection being made with the preparation, set and setting, and integration support someone receives.

We were also interested in looking beyond measures of depression and anxiety and take a broader view of wellbeing. We are curious about the impact of 5-Meo-DMT on a person’s mindfulness and perspective. We wanted to answer the question: Does 5-MeO-DMT help someone become more present and mindful, and does that help them find a more meaningful and fulfilling connection with their lives?

We are deeply grateful for the expertise and openheartedness of the UHN team. They have been incredible to work with. They’re deep expertise in psychology, spirituality, and psychedelics made them the perfect fit for this collaboration.

Participation in this study is completely voluntary and open to anyone attending an Awakening to Life 5-MeO-DMT Intensive .

How it works

Guests have the opportunity to participate at multiple levels of the study depending on their comfort level:

  • Level 1: Participate in anonymous before and after surveys, which take about 15 minutes to complete. Surveys are sent approximately two weeks before the retreat, and then again one week, one month, and three months afterwards
  • Level 2: Participants can opt-in to complete two short surveys the day after their final medicine session. These surveys are often found to be helpful in reflecting on one’s experience. They take about 5-10 minutes to complete and are anonymous.
  • Level 3: Participants can opt-in to have their preparation, on-site integration, and integration follow-up calls recorded for transcription. The transcriptions are anonymized by Enfold’s facilitators before being sent to the UHN team. These will be evaluated for more qualitative observations.

We greatly appreciate our guest’s consideration and participation in this important research. We hope this study will inform future research and bring important safety and efficacy considerations forward as 5-MeO-DMT continues to gain popularity.

Interested in participating? Email jesse@enfold.org to learn more.

Emma Hapke, UHN, Psychedelic Research Canada

Emma Hapke, MD, FRCPC

Dr. Emma Hapke, MD, FRCPC, is a psychiatrist, psychotherapist and psychedelic researcher. She started her career as an attending psychiatrist at CAMH in Toronto. Her specialty is women’s mental health and the treatment of developmental trauma, sexual trauma and complex PTSD. Dr. Hapke is also a lecturer at the University of Toronto. She has extensive training in multiple types of psychotherapy and has worked clinically with ketamine-assisted psychotherapy. She also has a growing interest in psychosocial oncology. Dr. Hapke works with MAPS as the principal investigator for the Montreal site of a phase III study examining MDMA-assisted psychotherapy for PTSD and is MAPS-trained to deliver MDMA-assisted psychotherapy. In the spring of 2021, Dr. Hapke joined UHN as an attending psychiatrist and is the co-founder of the UHN Psychedelic Psychotherapy Research Group.